IL173805A0 - Method and compositions for treating herpes infections - Google Patents

Method and compositions for treating herpes infections

Info

Publication number
IL173805A0
IL173805A0 IL173805A IL17380506A IL173805A0 IL 173805 A0 IL173805 A0 IL 173805A0 IL 173805 A IL173805 A IL 173805A IL 17380506 A IL17380506 A IL 17380506A IL 173805 A0 IL173805 A0 IL 173805A0
Authority
IL
Israel
Prior art keywords
compositions
treating herpes
herpes infections
infections
treating
Prior art date
Application number
IL173805A
Other languages
English (en)
Original Assignee
Talecris Biotherapeutics Inc
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talecris Biotherapeutics Inc, Bayer Healthcare Llc filed Critical Talecris Biotherapeutics Inc
Publication of IL173805A0 publication Critical patent/IL173805A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL173805A 2003-09-05 2006-02-19 Method and compositions for treating herpes infections IL173805A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/656,781 US6984492B2 (en) 2003-09-05 2003-09-05 Methods and compositions for treating herpes infections
PCT/US2004/028559 WO2005025617A2 (en) 2003-09-05 2004-09-02 Methods and compositions for treating herpes infections

Publications (1)

Publication Number Publication Date
IL173805A0 true IL173805A0 (en) 2006-07-05

Family

ID=34226428

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173805A IL173805A0 (en) 2003-09-05 2006-02-19 Method and compositions for treating herpes infections

Country Status (13)

Country Link
US (3) US6984492B2 (sk)
EP (1) EP1663309A2 (sk)
JP (1) JP2007504268A (sk)
KR (1) KR20060107509A (sk)
CN (1) CN1845756A (sk)
AU (1) AU2004272001A1 (sk)
BR (1) BRPI0414139A (sk)
CA (1) CA2537360A1 (sk)
IL (1) IL173805A0 (sk)
NO (1) NO20061184L (sk)
NZ (1) NZ546303A (sk)
WO (2) WO2005023303A1 (sk)
ZA (1) ZA200602738B (sk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2248825E (pt) * 2009-05-04 2013-01-07 Ribovax Biotechnologies Sa Fragmentos de antigénio ligantes a um anticorpo para uso no tratamento e diagnóstico de doenças oculares
WO2013023362A1 (zh) * 2011-08-16 2013-02-21 深圳市卫武光明生物制品有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
EP2912060B1 (en) * 2012-10-29 2019-12-25 The University of North Carolina at Chapel Hill Compositions and methods for inhibiting pathogen infection
US10829543B2 (en) 2012-10-29 2020-11-10 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
CA2942166A1 (en) 2014-03-03 2015-09-11 Albert Einstein College Of Medicine, Inc. Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
CA2950489C (en) 2014-06-26 2022-09-20 Heidelberg Immunotherapeutics Gmbh Topical application for an anti-hsv antibody
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2017083681A1 (en) 2015-11-13 2017-05-18 The University Or North Carolina At Chapel Hill Optimized crosslinkers for trapping a target on a substrate
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CA3118367A1 (en) * 2018-11-08 2020-05-14 The Board Of Trustees Of The University Of Illinois Treatment and diagnosis of autoantibody-mediated eye diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617379A (en) * 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4665159A (en) * 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4717564A (en) * 1985-11-07 1988-01-05 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
RU2051054C1 (ru) 1992-04-14 1995-12-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Способ получения препарата противогерпетического иммуноглобулина человека
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5681565A (en) * 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
AU6968098A (en) * 1997-04-15 1998-11-11 Advanced Viral Research Corp. Topical treatment of skin diseases and eye afflictions
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies

Also Published As

Publication number Publication date
US6984492B2 (en) 2006-01-10
ZA200602738B (en) 2008-06-25
US20090232798A1 (en) 2009-09-17
WO2005025617A3 (en) 2005-05-26
WO2005025617A2 (en) 2005-03-24
KR20060107509A (ko) 2006-10-13
CA2537360A1 (en) 2005-03-24
CN1845756A (zh) 2006-10-11
NZ546303A (en) 2009-03-31
NO20061184L (no) 2006-06-01
US20060198848A1 (en) 2006-09-07
WO2005023303A1 (en) 2005-03-17
JP2007504268A (ja) 2007-03-01
US20050053605A1 (en) 2005-03-10
AU2004272001A1 (en) 2005-03-24
EP1663309A2 (en) 2006-06-07
BRPI0414139A (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
IL173805A0 (en) Method and compositions for treating herpes infections
EP2671581B8 (en) Compositions and methods for treating cancer
HK1089676A1 (en) Formulations and methods for treating rhinosinusitis
HK1072360A1 (en) Compositions for use in methods for treating hearing loss
PT2286663T (pt) Métodos e composições para tratar infestação de ectoparasitas
IL164000A0 (en) Compositions and methods for treating emphysema
EP1633718A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-S
EP1468118A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
GB0609689D0 (en) Non-nucleotide compositions and method for treating pain
IL160010A0 (en) Methods and compositions for treating fungal infections
AU2003212894A1 (en) Compositions and methods for treating diarrhea
AU2003297573A8 (en) Compositions and methods for treating transplants
EP1684771A4 (en) COMPOSITION AND METHOD
SG118236A1 (en) Compositions and methods for treating coronavirus infection and SARS
EP1677754A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE EFFECTIVE DYSFUNCTION
AU2003296963A8 (en) Methods and compositions for treating and preventing ear infections
AU2003239132A8 (en) Methods and compositions for preventing and treating microbial infections
EP1626711A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
ZA200602275B (en) Composition and method for treating bezoar and trichobezoar
AU2003238905A1 (en) Surface treating compositions and methods for using same
AU2003295574A8 (en) Method and compositions for temporarily incapaciting subjets
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
AU2003275433A8 (en) Compositions and methods for treating pain
EP1594473A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF AGE-RELATED DISEASES